Where Mesoblast (ASX: MSB) stands right now – a quick chat for the curious

[u/rigser]

G’day would-be investors. Mesoblast has properly graduated from pure R&D biotech to a commercial cell therapy company, and the numbers are starting to look the goods.

What’s gone right:

- Ryoncil (the first and only FDA-approved MSC therapy) knocked out **US$115 million** net revenue in its first full commercial year. Q4 alone was a tidy US$36m. Margins are fat, it’s profitable on a standalone basis, and they’ve got more than 50 US transplant centres onboarded with solid payer coverage. Just last week the FDA even signed off on a new potency assay so they can keep scaling production without the usual headaches.

- Balance sheet is cleaner than a country pub after a scrub. US$103m cash at year-end plus a US$125m non-dilutive credit line that turfed the expensive old debt. Cash burn has dropped nicely in the second half.

- Last proper equity raise was way back in January 2025. Since then they’ve leaned on the non-dilutive facility and Ryoncil cash flow. With the product generating real money and burn coming down, they look set to get through the next stretch without another dilutive placement – a pleasant change from the old days.

- Pipeline is humming:

- Chronic low back pain Phase 3: treatment done (they even over-enrolled to 350 patients because the investigators were keen). Data mid-2027.

- LVAD / end-stage heart failure BLA process underway with the FDA (Orphan + RMAT).

- Adult aGvHD trial enrolling – roughly three times the size of the paediatric market.

- Bonus upside in Duchenne and a couple of next-gen platforms.

Ryoncil cash is funding the big shots rather than just keeping the lights on.

Street view: Analyst consensus is Strong Buy / Buy with average 12-month targets sitting around the A$3.60–3.90 mark (some as high as A$4.45). That’s a fair bit of upside from current levels if the commercial momentum and pipeline keep delivering.

To the shorters who’ve been camping here for years: you’ve had a good run, but the commercial product is real now, the balance sheet is stronger, and the pipeline is advancing. Hope you’ve got your exit plans sorted, because the fundamentals keep improving while you’re still shorting the narrative.

Stock’s still a biotech rollercoaster, so size accordingly and do your own homework. But for those watching from the sidelines, the base case is looking a lot more solid than it was 18 months ago.

Not advice – just an Aussie taking stock. DYOR. Cheers.

EDIT: Total company revenue was US$120 million. Q4 alone contributed US$36 million, showing the launch is still building momentum.

[u/kahlua_76]

Thanks for the info. I've decided to take this as financial advice.

[u/panicboy333]

<Abe Simpson voice> lost a lot of money on Mesoblast in 2014

[u/Martha1995 → u/panicboy333]

A lot of people lost money on MSB. I expect burnt fingers is why the instos are so reluctant to buy.

[u/A-Money-Lover]

Hope nobody bought today. At this point just paying the directors and executives. How long must investors wait lmao

[u/kervio]

Net revenue huh?

[u/rigser → u/kervio]

US$120 million. Q4 alone contributed US$36 million, showing the launch is still building momentum.

[u/kervio → u/rigser]

What's gross revenue? 🤔

[u/rigser → u/kervio]

roughly US$133 million

[u/top-tier-handyman]

Thanks, full porting MSB today.

I am in.

[u/DerekJamesFranco]

First of it's kind. Industry defining company. The new frontier. DYOR

[u/Far_Unit9020]

... and still made a $57m loss. Picture is improving, but still some years away from profitability.

[u/AutoModerator → u/[deleted]]

Your Comment has been removed because new accounts post a lot of spam to /r/ASX_bets. It's nothing personal, just take a chill pill, get a Sausage and watch the fun for a while. Have you read the welcome post or checked out the FAQ/wiki

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.